Data demonstrated that a significant proportion of healthcare workers have the ability to neutralize Ebola virus (EBOV), despite never having developed Ebola virus disease symptoms, highlighting an important and poorly documented aspect of EBOV infection and progression.
Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.
Two new studies are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
For the first time, scientists discovered a new ebolavirus species in a host prior to detection in an infected human or sick animal.
The monoclonal antibody, known as mAb114, is likely to be used in the current Ebola outbreak in Democratic Republic of Congo (DRC).
There are no proven treatments for Ebola. Scientists are hopeful that that therapeutic antibodies could be the best way to stop this virus.
Important scientific questions remain unanswered in the effort to develop a safe and effective Ebola vaccine, according to members of an international Ebola research consortium.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists.
A new study is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication.
Researechers compared immune responses induced by Ebola virus glycoprotein subunit vaccines via intradermal immunization with microneedle (MN) patches and the conventional intramuscular injection in mice.